<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-id journal-id-type="pmc">brjcancer</journal-id><journal-title>British Journal of Cancer</journal-title><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">9400948</article-id><article-id pub-id-type="pmc">2228187</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Phase I study of sequentially administered topoisomerase I inhibitor (irinotecan) and topoisomerase II inhibitor (etoposide) for metastatic non-small-cell lung cancer.</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Ando</surname><given-names>M.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Eguchi</surname><given-names>K.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Shinkai</surname><given-names>T.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Tamura</surname><given-names>T.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Ohe</surname><given-names>Y.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Yamamoto</surname><given-names>N.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Kurata</surname><given-names>T.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Kasai</surname><given-names>T.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Ohmatsu</surname><given-names>H.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Kubota</surname><given-names>K.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Sekine</surname><given-names>I.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Hojo</surname><given-names>N.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Matsumoto</surname><given-names>T.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Kodama</surname><given-names>T.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Kakinuma</surname><given-names>R.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Nishiwaki</surname><given-names>Y.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Saijo</surname><given-names>N.</given-names></name></contrib></contrib-group><aff>The Department of Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.</aff><pub-date pub-type="ppub"><year>1997</year></pub-date><volume>76</volume><issue>11</issue><fpage>1494</fpage><lpage>1499</lpage><abstract><p>We conducted a phase I study of irinotecan (CPT-11) and etoposide (VP-16) given sequentially to untreated patients with metastatic non-small-cell lung cancer. Arm A: CPT-11 was given over 90 min on days 1-3 and VP-16 was given over 60 min on days 4-6. Arm B: VP-16 was given on days 1-3 and CPT-11 on days 4-6. G-CSF was given to all patients daily on days 7-17. Twenty-seven patients were entered randomly at the two arms. The major dose-limiting toxicities in arms A and B were granulocytopenia and diarrhoea. Transient elevations of transaminases and bilirubin were observed in both arms. The degree of the toxicities did not differ between the two arms. The maximum tolerated doses (MTDs) were 60 mg m-2 CPT-11 and 60 mg m-2 VP-16 in both arms. Of the 13 patients who received more than two cycles, two out of five achieved partial response (PR) at the first level of arm A and one out of four achieved PR at the second level of arm B. We conclude that these schedules of sequential CPT-11 and VP-16 administration were inappropriate because of severe toxicities.</p><sec sec-type="scanned-figures"><title>Images</title><fig id="F1"><label>Figure 1</label><graphic xlink:href="brjcancer00175-0107-a" xlink:role="1497"/></fig><fig id="F2"><label>Figure 2</label><graphic xlink:href="brjcancer00175-0107-b" xlink:role="1497"/></fig></sec></abstract></article-meta></front><body><supplementary-material content-type="scanned-pages"><graphic xlink:href="brjcancer00175-0104.tif" xlink:title="scanned-page" xlink:role="1494" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="brjcancer00175-0105.tif" xlink:title="scanned-page" xlink:role="1495" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="brjcancer00175-0106.tif" xlink:title="scanned-page" xlink:role="1496" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="brjcancer00175-0107.tif" xlink:title="scanned-page" xlink:role="1497" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="brjcancer00175-0108.tif" xlink:title="scanned-page" xlink:role="1498" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="brjcancer00175-0109.tif" xlink:title="scanned-page" xlink:role="1499" mimetype="image" mime-subtype="tiff"/></supplementary-material></body></article>

